These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
190 related articles for article (PubMed ID: 22446619)
21. The tumour suppressor SOX11 is associated with improved survival among high grade epithelial ovarian cancers and is regulated by reversible promoter methylation. Sernbo S; Gustavsson E; Brennan DJ; Gallagher WM; Rexhepaj E; Rydnert F; Jirström K; Borrebaeck CA; Ek S BMC Cancer; 2011 Sep; 11():405. PubMed ID: 21943380 [TBL] [Abstract][Full Text] [Related]
22. LINE1 and Alu repetitive element DNA methylation in tumors and white blood cells from epithelial ovarian cancer patients. Akers SN; Moysich K; Zhang W; Collamat Lai G; Miller A; Lele S; Odunsi K; Karpf AR Gynecol Oncol; 2014 Feb; 132(2):462-7. PubMed ID: 24374023 [TBL] [Abstract][Full Text] [Related]
24. Promoter Hypermethylation of FANCF and Susceptibility and Prognosis of Epithelial Ovarian Cancer. Ding JJ; Wang G; Shi WX; Zhou HH; Zhao EF Reprod Sci; 2016 Jan; 23(1):24-30. PubMed ID: 26507869 [TBL] [Abstract][Full Text] [Related]
25. miR-211 suppresses epithelial ovarian cancer proliferation and cell-cycle progression by targeting Cyclin D1 and CDK6. Xia B; Yang S; Liu T; Lou G Mol Cancer; 2015 Mar; 14():57. PubMed ID: 25889927 [TBL] [Abstract][Full Text] [Related]
26. Claudin-4 overexpression in epithelial ovarian cancer is associated with hypomethylation and is a potential target for modulation of tight junction barrier function using a C-terminal fragment of Clostridium perfringens enterotoxin. Litkouhi B; Kwong J; Lo CM; Smedley JG; McClane BA; Aponte M; Gao Z; Sarno JL; Hinners J; Welch WR; Berkowitz RS; Mok SC; Garner EI Neoplasia; 2007 Apr; 9(4):304-14. PubMed ID: 17460774 [TBL] [Abstract][Full Text] [Related]
27. RUNX3 and CAMK2N1 hypermethylation as prognostic marker for epithelial ovarian cancer. Häfner N; Steinbach D; Jansen L; Diebolder H; Dürst M; Runnebaum IB Int J Cancer; 2016 Jan; 138(1):217-28. PubMed ID: 26175272 [TBL] [Abstract][Full Text] [Related]
28. Genome-wide investigation of regional blood-based DNA methylation adjusted for complete blood counts implicates BNC2 in ovarian cancer. Winham SJ; Armasu SM; Cicek MS; Larson MC; Cunningham JM; Kalli KR; Fridley BL; Goode EL Genet Epidemiol; 2014 Jul; 38(5):457-66. PubMed ID: 24853948 [TBL] [Abstract][Full Text] [Related]
29. MicroRNA-145 targets TRIM2 and exerts tumor-suppressing functions in epithelial ovarian cancer. Chen X; Dong C; Law PT; Chan MT; Su Z; Wang S; Wu WK; Xu H Gynecol Oncol; 2015 Dec; 139(3):513-9. PubMed ID: 26472353 [TBL] [Abstract][Full Text] [Related]
30. Epigenetic activation of POTE genes in ovarian cancer. Sharma A; Albahrani M; Zhang W; Kufel CN; James SR; Odunsi K; Klinkebiel D; Karpf AR Epigenetics; 2019 Feb; 14(2):185-197. PubMed ID: 30764732 [TBL] [Abstract][Full Text] [Related]
31. Epigenetic silencing of DKK2 and Wnt signal pathway components in human ovarian carcinoma. Zhu J; Zhang S; Gu L; Di W Carcinogenesis; 2012 Dec; 33(12):2334-43. PubMed ID: 22964660 [TBL] [Abstract][Full Text] [Related]
32. BORIS/CTCFL mRNA isoform expression and epigenetic regulation in epithelial ovarian cancer. Link PA; Zhang W; Odunsi K; Karpf AR Cancer Immun; 2013; 13():6. PubMed ID: 23390377 [TBL] [Abstract][Full Text] [Related]
33. Relationship between promoter methylation & tissue expression of MGMT gene in ovarian cancer. Shilpa V; Bhagat R; Premalata CS; Pallavi VR; Ramesh G; Krishnamoorthy L Indian J Med Res; 2014 Nov; 140(5):616-23. PubMed ID: 25579142 [TBL] [Abstract][Full Text] [Related]
34. Intertumor and intratumor NY-ESO-1 expression heterogeneity is associated with promoter-specific and global DNA methylation status in ovarian cancer. Woloszynska-Read A; Mhawech-Fauceglia P; Yu J; Odunsi K; Karpf AR Clin Cancer Res; 2008 Jun; 14(11):3283-90. PubMed ID: 18519754 [TBL] [Abstract][Full Text] [Related]
35. LINE-1 hypomethylation level as a potential prognostic factor for epithelial ovarian cancer. Pattamadilok J; Huapai N; Rattanatanyong P; Vasurattana A; Triratanachat S; Tresukosol D; Mutirangura A Int J Gynecol Cancer; 2008; 18(4):711-7. PubMed ID: 17944913 [TBL] [Abstract][Full Text] [Related]
36. The PI3K/AKT/mTOR pathway is a potential predictor of distinct invasive and migratory capacities in human ovarian cancer cell lines. Bai H; Li H; Li W; Gui T; Yang J; Cao D; Shen K Oncotarget; 2015 Sep; 6(28):25520-32. PubMed ID: 26267321 [TBL] [Abstract][Full Text] [Related]
37. Targeting HSF1 leads to an antitumor effect in human epithelial ovarian cancer. Chen YF; Wang SY; Yang YH; Zheng J; Liu T; Wang L Int J Mol Med; 2017 Jun; 39(6):1564-1570. PubMed ID: 28487934 [TBL] [Abstract][Full Text] [Related]
38. Dysregulation of TMPRSS3 and TNFRSF11B correlates with tumorigenesis and poor prognosis in patients with breast cancer. Luo P; Lu G; Fan LL; Zhong X; Yang H; Xie R; Lv Z; Lv QZ; Fu D; Yang LX; Ma Y Oncol Rep; 2017 Apr; 37(4):2057-2062. PubMed ID: 28260080 [TBL] [Abstract][Full Text] [Related]
39. Epigenetic analysis of sporadic and Lynch-associated ovarian cancers reveals histology-specific patterns of DNA methylation. Niskakoski A; Kaur S; Staff S; Renkonen-Sinisalo L; Lassus H; Järvinen HJ; Mecklin JP; Bützow R; Peltomäki P Epigenetics; 2014 Dec; 9(12):1577-87. PubMed ID: 25625843 [TBL] [Abstract][Full Text] [Related]
40. Epigenetic alteration of p16 and retinoic acid receptor beta genes in the development of epithelial ovarian carcinoma. Bhagat R; Kumar SS; Vaderhobli S; Premalata CS; Pallavi VR; Ramesh G; Krishnamoorthy L Tumour Biol; 2014 Sep; 35(9):9069-78. PubMed ID: 24913706 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]